INTRODUCTION: Few studies have examined prognostic factors that have an impact on outcomes in anterior skull base surgery by multivariate analysis. METHODS: We retrospectively examined our institution's skull base experience from 1973-2000. RESULTS: During this time, 166 patients underwent an anterior skull base resection for malignancy (median age, 53 years; range, 6-92 years). The 5-year relapse-free and disease-specific survival was 41% and 57% (median follow-up, 53 months). Multivariate analysis found that dural invasion, primary histologic diagnosis, and margin status had a significant impact on relapse-free and disease-specific survival. CONCLUSIONS: These data indicate that patients with anterior skull base malignancies are treated successfully with skull base surgery. Patients demonstrating adverse prognostic variables such as dural invasion, adverse histologic findings, and/or positive margins should be considered for the addition of adjuvant therapy or innovative therapies as they become available in the future. Copyright 2003 Wiley Periodicals, Inc. Head Neck 25: 515-520, 2003
INTRODUCTION: Few studies have examined prognostic factors that have an impact on outcomes in anterior skull base surgery by multivariate analysis. METHODS: We retrospectively examined our institution's skull base experience from 1973-2000. RESULTS: During this time, 166 patients underwent an anterior skull base resection for malignancy (median age, 53 years; range, 6-92 years). The 5-year relapse-free and disease-specific survival was 41% and 57% (median follow-up, 53 months). Multivariate analysis found that dural invasion, primary histologic diagnosis, and margin status had a significant impact on relapse-free and disease-specific survival. CONCLUSIONS: These data indicate that patients with anterior skull base malignancies are treated successfully with skull base surgery. Patients demonstrating adverse prognostic variables such as dural invasion, adverse histologic findings, and/or positive margins should be considered for the addition of adjuvant therapy or innovative therapies as they become available in the future. Copyright 2003 Wiley Periodicals, Inc. Head Neck 25: 515-520, 2003
Authors: Hedyeh Ziai; Eugene Yu; Terence Fu; Nidal Muhanna; Eric Monteiro; Allan Vescan; Gelareh Zadeh; Ian J Witterick; David P Goldstein; Fred Gentili; John R de Almeida Journal: J Neurol Surg B Skull Base Date: 2017-12-29
Authors: Omer J Ungar; Avraham Abergel; Ahmad Safadi; Arik Zaretzki; Ravit Yanko-Arzi; Dan M Fliss Journal: J Neurol Surg B Skull Base Date: 2019-02-06
Authors: Jennifer R Cracchiolo; Krupa Patel; Jocelyn C Migliacci; Luc T Morris; Ian Ganly; Benjamin R Roman; Sean M McBride; Viviane S Tabar; Marc A Cohen Journal: J Surg Oncol Date: 2017-11-28 Impact factor: 3.454